Quick Answer
Whitehawk Therapeutics, Inc. reported Diluted EPS of $0.33 per share (loss) for fiscal year 2025.
Whitehawk Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.33 | +86.0% |
| 2024 | -$2.36 | +3.3% |
| 2023 | -$2.44 | +9.3% |
| 2022 | -$2.69 | +78.3% |
| 2021 | -$12.41 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.26 | +43.5% | +65.8% |
| June 30, 2025 | -$0.76 | -40.7% | -141.5% |
| March 31, 2025 | $1.83 | +369.1% | +497.8% |
| September 30, 2024 | -$0.46 | +23.3% | +14.8% |
| June 30, 2024 | -$0.54 | +19.4% | +20.6% |
| March 31, 2024 | -$0.68 | -19.3% | -13.3% |
| September 30, 2023 | -$0.60 | +11.8% | +10.4% |
| June 30, 2023 | -$0.67 | +23.0% | -17.5% |
- Whitehawk Therapeutics, Inc. showed an increase of +86.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Whitehawk Therapeutics, Inc.’s diluted eps has grown by 97.3% (from $12.41 per share (loss) to $0.33 per share (loss)).
- The most recent figure is from Whitehawk Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: